Dr. L. Alison McInnes is Vice President, Scientific Affairs at Osmind. She is a nationally recognized expert in psychiatry and mood and anxiety disorders, having specialized in treating refractory disease for over a decade. She is additionally an expert in ketamine treatment and psychedelic medicine. Dr. McInnes received her bachelor’s and master’s degrees from Stanford University and her MD from Columbia University graduating with honors (Alpha Omega Alpha). She completed residency at UCSF and received both a VA Research Fellowship and Howard Hughes Physician Research Fellowship at that time. She continued to do research and became an Associate Professor of Psychiatry at Mount Sinai School of Medicine where she ran a NIMH-funded lab studying the genetics of behavioral disorders. She then went on to found and direct a multi-site ketamine therapy program at Kaiser Permanente in Northern California before coming to Osmind. She is a member of the American College of Neuropsychopharmacology and has authored two important papers describing outcomes of ketamine infusion therapy in the largest real-world data sets examined to date. Other memberships include ASKP3, APPA, and APA. In her current clinical practice, she focuses on difficult-to-treat mood disorders and complex cases.